TG Therapeutics (NASDAQ:TGTX) Issues Earnings Results

TG Therapeutics (NASDAQ:TGTX) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26), Briefing.com reports. The company had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. TG Therapeutics’s revenue for the quarter was up 70.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 earnings per share.

Here are the key takeaways from TG Therapeutics’ conference call:

• BRIUMVI sales exceeded expectations, with U.S. net product revenue of approximately $228 million, up 17% sequentially and more than 64% year over year. TG Therapeutics raised 2026 U.S. revenue guidance to $890 million–$905 million and global revenue guidance to approximately $950 million.
• Commercial momentum remains strong, including record new patient starts, expanding physician adoption, improving persistence, and increasing use in treatment-naive patients. Management expects to exit 2026 at a quarterly U.S. revenue run rate above $250 million, implying its first billion-dollar annualized run rate.
• The company reported positive Phase III ENHANCE results supporting a simplified single-infusion BRIUMVI initiation schedule, potentially available by mid-2027, while its quarterly subcutaneous formulation remains on track for Phase III results around year-end 2026 or early 2027 and could expand the addressable market substantially.
• TG is expanding BRIUMVI beyond relapsing multiple sclerosis, advancing a registration-directed Phase II myasthenia gravis study and a Phase II treatment-resistant schizophrenia study. The azer-cel allogeneic CAR-T program has enrolled more than 20 patients across MS and other B-cell-mediated diseases, with a clinical update expected in the second half of 2026.
• Reported operating income and net income were limited by approximately $55 million of subcutaneous and secondary-source manufacturing charges in the quarter; TG expects about $100 million of such expenses for full-year 2026, in addition to $350 million–$400 million of underlying operating expenses.

TG Therapeutics Stock Down 11.3%

Shares of NASDAQ:TGTX opened at $46.17 on Tuesday. The firm has a market capitalization of $7.07 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 1.30 and a beta of 1.62. The business has a 50 day simple moving average of $50.62 and a two-hundred day simple moving average of $39.07. TG Therapeutics has a 1 year low of $25.28 and a 1 year high of $59.30. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. B. Riley Financial raised their price target on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Bank of America lifted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $58.50.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TGTX. Maryland State Retirement & Pension System lifted its holdings in shares of TG Therapeutics by 2.0% in the 4th quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company’s stock valued at $593,000 after buying an additional 393 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in TG Therapeutics by 1.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after acquiring an additional 441 shares during the period. Smartleaf Asset Management LLC grew its holdings in TG Therapeutics by 16.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 454 shares during the period. Lido Advisors LLC raised its position in TG Therapeutics by 3.9% during the third quarter. Lido Advisors LLC now owns 14,276 shares of the biopharmaceutical company’s stock valued at $516,000 after acquiring an additional 541 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 573 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

Key Headlines Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: BRIUMVI sales exceeded expectations. Second-quarter global revenue reached approximately $240 million, including about $228 million in U.S. BRIUMVI net product revenue—up 64% year over year and above the roughly $230 million total-revenue consensus. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Management raised its 2026 outlook. TG Therapeutics now expects approximately $950 million in total 2026 revenue, ahead of the approximately $942 million consensus estimate, and increased its U.S. BRIUMVI revenue target to approximately $890 million-$905 million. The CEO also said BRIUMVI remains on track to become a $1 billion U.S. product. TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Future growth opportunities remain. The company’s planned subcutaneous BRIUMVI formulation could broaden the multiple sclerosis market and potentially improve margins, with Phase 3 data expected in late 2026 or early 2027. TG Therapeutics: Why I’m Staying Long After The Q2 Selloff
• Neutral Sentiment: Revenue growth was strong, rising 70.2% from the prior-year quarter, and some investors appeared willing to look past the earnings miss because of BRIUMVI’s commercial momentum.
• Negative Sentiment: Quarterly EPS fell short of expectations. TG Therapeutics reported adjusted earnings of $0.05 per share, versus consensus estimates ranging from $0.31 to $0.41 and $0.17 a year earlier. Manufacturing investments weighed on profitability, creating near-term concern despite the improved sales outlook. TGTX Q2 Earnings Lag, Sales Rise Year Over Year, 2026 View Raised

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.